Hansa Biopharma AB (HNSA) Price & Analysis

Compare

15 Followers

HNSA Stock Chart & Stats

kr29.12

-kr0.04(-0.17%)

At close: Mar 06 4:00 PM EST

kr29.12

-kr0.04(-0.17%)

Day’s Range― - ―

52-Week Rangekr19.58 - kr42.98

Previous CloseN/A

Volume97.73K

Average Volume (3M)792.96K

Market Cap

kr3.00B

Enterprise Valuekr2.63B

Total Cash (Recent Filing)kr701.08M

Total Debt (Recent Filing)kr933.82M

Price to Earnings (P/E)―

Beta0.58

Next Earnings

Apr 23, 2026

EPS Estimate

-1.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.62

Shares Outstanding101,763,220

10 Day Avg. Volume714,369

30 Day Avg. Volume792,961

Financial Highlights & Ratios

PEG Ratio0.11

Price to Book (P/B)-33.16

Price to Sales (P/S)12.55

P/FCF Ratio-5.08

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr86.00

Price Target Upside195.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-5.78

Revenue Forecast (FY)kr307.99M

Bulls Say, Bears Say

Bulls Say

Gene Therapy Pre-treatment UtilityDemonstrated ability to allow patients with pre-existing neutralizing antibodies to receive viral gene therapies supports collaborations to use the therapy as a pre-treatment option and expand addressable patient populations.

Guillain-Barré Program PotentialStrong Phase 2 data for a second-generation enzyme support development for Guillain-Barré Syndrome, presenting a meaningful opportunity to expand the company's clinical pipeline and address an unmet need.

Transplant EfficacyImlifidase enables highly sensitized transplant patients to access a wider range of donor organs, and ConfIdeS study results showed post-treatment kidney function that implies graft survival broadly comparable to the general transplant population.

Bears Say

Clinical Data IntegrityImbalances in transplanted patients between treatment and control groups and surprising placebo responses in related trials raise concerns about study design and data reliability that could undermine regulatory confidence.

Commercial Execution RiskReorganization of the European commercial and medical teams may create temporary headwinds and softer sales performance in core European markets.

Regulatory UncertaintyAssignment of a standard review combined with a raised evidentiary bar at the regulator increases the risk that submissions relying on surrogate endpoints will face extended scrutiny or rejection.

Hansa Biopharma AB News

Hansa Biopharma to Present Commercial Strategy at Redeye Life Science Event

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an update. Hansa Biopharma AB, a commercial-stage Swedish biopharmaceutical group...

2d ago

Hansa Biopharma to Spotlight Immunomodulatory Platform at DNB Carnegie Healthcare Conference

The latest update is out from Hansa Biopharma AB ( ($SE:HNSA) ). Hansa Biopharma AB, a Swedish commercial-stage...

5d ago

Hansa Biopharma leadership to spotlight growth strategy at LSX Investival USA

Hansa Biopharma AB ( ($SE:HNSA) ) has shared an announcement. Hansa Biopharma AB will showcase its leadership in...

6d ago

Hansa Biopharma to Spotlight Immunomodulatory Platform at Leerink Global Healthcare Conference

An update from Hansa Biopharma AB ( ($SE:HNSA) ) is now available. Hansa Biopharma AB, a commercial-stage biopharmaceutical...

9d ago

Imlifidase: Extended FDA Review Seen as Timing-Driven, Not Risk-Driven, Supporting Buy Rating on Strong Unmet-Need and Efficacy Profile

Douglas Tsao, an analyst from H.C. Wainwright, maintained the Buy rating on Hansa Biopharma AB. The associated price...

10d ago

Hansa Biopharma Secures FDA PDUFA Date for Imlifidase in High-Risk Kidney Transplant Patients

Hansa Biopharma AB ( ($SE:HNSA) ) has shared an update. Hansa Biopharma has received a Prescription Drug User...

11d ago

Hansa Biopharma’s Anti-GBM Phase 3 Trial Termination: What Investors Should Know

Hansa Biopharma ($SE:HNSA) announced an update on their ongoing clinical study. Hansa Biopharma (SE:HNSA) has updated its Phase...

11d ago

HNSA

Hansa Biopharma to Present Corporate Strategy at TD Cowen Health Care Conference

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an announcement. Hansa Biopharma will showcase its corporate strategy and...

20d ago

Imlifidase’s Accelerated Approval Momentum and Long‑Term Graft Outcomes Support a Buy Rating on Hansa Biopharma

Hansa Biopharma AB, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao...

24d ago

Hansa Biopharma Wins FDA Review Acceptance for Imlifidase Kidney Transplant Therapy

An announcement from Hansa Biopharma AB ( ($SE:HNSA) ) is now available. Hansa Biopharma has had its Biologics...

25d ago

Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Hansa Biopharma (HNSBF) to SEK 103 from...

1M ago

Hansa Biopharma initiated with an Outperform at Wedbush

Wedbush initiated coverage of Hansa Biopharma (HNSBF) with an Outperform rating and SEK 69 price target The firm...

2M ago

HNSA FAQ

What was Hansa Biopharma AB’s price range in the past 12 months?

Hansa Biopharma AB lowest stock price was kr19.58 and its highest was kr42.98 in the past 12 months.

What is Hansa Biopharma AB’s market cap?

Hansa Biopharma AB’s market cap is kr3.00B.

When is Hansa Biopharma AB’s upcoming earnings report date?

Hansa Biopharma AB’s upcoming earnings report date is Apr 23, 2026 which is in 39 days.

How were Hansa Biopharma AB’s earnings last quarter?

Hansa Biopharma AB released its earnings results on Feb 11, 2026. The company reported -kr1.62 earnings per share for the quarter, missing the consensus estimate of -kr1.576 by -kr0.044.

Is Hansa Biopharma AB overvalued?

According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hansa Biopharma AB pay dividends?

Hansa Biopharma AB does not currently pay dividends.

What is Hansa Biopharma AB’s EPS estimate?

Hansa Biopharma AB’s EPS estimate is -1.48.

How many shares outstanding does Hansa Biopharma AB have?

Hansa Biopharma AB has 101,763,220 shares outstanding.

What happened to Hansa Biopharma AB’s price movement after its last earnings report?

Hansa Biopharma AB reported an EPS of -kr1.62 in its last earnings report, missing expectations of -kr1.576. Following the earnings report the stock price went up 4.759%.

Which hedge fund is a major shareholder of Hansa Biopharma AB?

Currently, no hedge funds are holding shares in SE:HNSA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Hansa Biopharma AB (HNSA) Earnings & Revenues

Historic Earnings Reports

HNSA Stock 12 Month Forecast

Average Price Target

kr86.00

▲(195.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"kr21","104":"kr104","41.75":"kr41.8","62.5":"kr62.5","83.25":"kr83.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr103.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr86.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr69.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,41.75,62.5,83.25,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32,37.46153846153846,42.92307692307692,48.38461538461539,53.84615384615385,59.30769230769231,64.76923076923077,70.23076923076923,75.6923076923077,81.15384615384616,86.61538461538461,92.07692307692308,97.53846153846155,{"y":103,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32,36.15384615384615,40.30769230769231,44.46153846153847,48.61538461538461,52.769230769230774,56.92307692307693,61.07692307692308,65.23076923076923,69.38461538461539,73.53846153846155,77.6923076923077,81.84615384615385,{"y":86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32,34.84615384615385,37.69230769230769,40.53846153846154,43.38461538461539,46.23076923076923,49.07692307692308,51.92307692307692,54.769230769230774,57.61538461538461,60.46153846153847,63.30769230769231,66.15384615384616,{"y":69,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >